查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1192997

糖尿病药物市场：副产品（注射剂、口服糖尿病药物）：2020-2030 年全球机会分析和行业预测

Diabetes Therapeutics Market By Product (Injectables, Oral antidiabetic Drugs): Global Opportunity Analysis and Industry Forecast, 2020-2030
出版日期: | 出版商: Allied Market Research | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

2020 年全球糖尿病药物市场价值 1180.633 亿美元，从 2021 年到 2030 年以 10.4% 的复合年增长率增长，预计到 2030 年将达到 3179.15 亿美元

糖尿病是一种血糖水平异常的慢性代谢性疾病。 糖尿病药物是糖尿病患者用来维持体内血糖水平的药物。

由于糖尿病、高肥胖、久坐不动的生活方式和其他慢性病的患病率上升，预计全球糖尿病药物市场在不久的将来将出现显着增长。 例如，根据国际糖尿病联合会 (IDF) 糖尿病地图集，到 2021 年将有大约 5.37 亿成年人（20-79 岁）患有糖尿病。 此外，不断增长的老年人口导致了糖尿病药物市场的增长。 然而，抗糖尿病药物的副作用阻碍了预测期内的市场增长。 相反，增加糖尿病领域研发活动的资金预计将为市场参与者提供有利可图的机会。

内容

第一章介绍

第 2 章执行摘要

第 3 章市场概述

  • 市场定义和范围
  • 主要发现
    • 主要投资领域
  • 波特的五力分析
  • 主要公司的定位
  • 市场动态
    • 司机
    • 约束因素
    • 机会
  • COVID-19 影响分析

第 4 章糖尿病药物市场：按产品分类

  • 概览
    • 市场规模和预测
  • 注射
    • 主要市场趋势、增长因素和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类
  • 口服降糖药
    • 主要市场趋势、增长动力和机遇
    • 市场规模和预测：按地区
    • 市场分析：按国家/地区分类

第 5 章糖尿病药物市场：按地区

  • 概览
    • 市场规模和预测
  • 北美
    • 主要趋势和机遇
    • 北美市场规模和预测：按产品
    • 北美市场规模和预测：按国家/地区分类
      • 美国
      • 加拿大
      • 墨西哥
  • 欧洲
    • 主要趋势和机会
    • 欧洲市场规模和预测：按产品
    • 欧洲市场规模和预测：按国家/地区分类
      • 德国
      • 法国
      • 英国
      • 意大利
      • 西班牙
      • 其他欧洲地区
  • 亚太地区
    • 主要趋势和机会
    • 亚太市场规模和预测：按产品
    • 亚太地区的市场规模和预测：按国家/地区分类
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 其他亚太地区
  • 拉美
    • 主要趋势和机会
    • LAMEA 市场规模和预测：按产品
    • LAMEA 市场规模和预测：按国家/地区分类
      • 巴西
      • 沙特阿拉伯
      • 南非
      • 其他拉美地区

第6章业务条件

  • 简介
  • 关键成功策略
  • 10 家主要公司的产品映射
  • 比赛仪表板
  • 竞争热图
  • 主要发展

第七章公司简介

  • ASTRAZENECA PLC
  • BOEHRINGER INGELHEIM GMBH
  • ELI LILLY AND COMPANY
  • GLAXOSMITHKLINE PLC
  • NOVARTIS AG
  • NOVO NORDISK
  • SANOFI S.A.
  • TAKEDA PHARMACEUTICAL COMPANY LIMITED
  • johnson and johnson md&d
  • MERCK and CO., INC.
Product Code: A03202

The global diabetes therapeutics market was valued at $118,063.3 million in 2020, and is projected to reach $317,915 million by 2030, registering a CAGR of 10.4% from 2021 to 2030. Diabetes is a chronic metabolic disorder in which there are abnormalities in blood glucose levels. Diabetes therapeutics are drugs used by diabetic patients to conserve the blood glucose levels in the body.

The global diabetes therapeutics market is expected to register substantial growth in the near future, owing to rise in prevalence of diabetes, high obesity, sedentary lifestyles, and other chronic conditions. For instance, according to International Diabetes Federation (IDF),Diabetes Atlas, in 2021, approximately 537 million adults (20-79 years of age) were living with diabetes.  Furthermore, rise in geriatric population led to an increase in growth of diabetes therapeutics market. However, side effects caused by anti-diabetes medication hamper the market growth during the forecast period. Conversely, increase in funding for R&D activities in diabetes sector is expected to offer remunerative opportunities for market players.

The diabetes therapeutics market is segmented into product and region. By product, the market is categorized into injectables and oral-antidiabetic drugs (OAD). By region, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, Taiwan, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players operating in the global diabetes therapeutics market include Astrazeneca Plc., Boehringer Ingelheim GmbH, Eli Lilly and Company, Glaxosmithkline Plc., Johnson & Johnson, Merck & Co., Inc., Novartis Ag ,Novo Nordisk, Sanofi S.A., and Takeda Pharmaceutical Company Limited.

KEY BENEFITS FOR STAKEHOLDERS

  • The report provides an in-depth analysis of the global diabetes therapeutics market size along with the current trends and future estimations to elucidate the future investment pockets.
  • It offers market analysis from 2021 to 2030, which is expected to enable the stakeholders to capitalize on the prevailing opportunities in the market.
  • A comprehensive analysis of the region helps to understand the regional market, facilitate strategic business planning, and determine prevailing opportunities.
  • The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global diabetes therapeutics market growth.

Key Market Segments

By Product

  • Injectables
  • Oral antidiabetic Drugs

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest Of Asia Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • ASTRAZENECA PLC
    • BOEHRINGER INGELHEIM GMBH
    • ELI LILLY AND COMPANY
    • GLAXOSMITHKLINE PLC
    • NOVARTIS AG
    • NOVO NORDISK
    • SANOFI S.A.
    • TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • johnson and johnson md&d
    • MERCK and CO., INC.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: DIABETES THERAPEUTICS MARKET, BY PRODUCT

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Injectables
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Oral antidiabetic Drugs
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country

CHAPTER 5: DIABETES THERAPEUTICS MARKET, BY REGION

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 North America
    • 5.2.1 Key trends and opportunities
    • 5.2.2 North America Market size and forecast, by Product
    • 5.2.3 North America Market size and forecast, by country
      • 5.2.3.1 U.S.
      • 5.2.3.1.1 Market size and forecast, by Product
      • 5.2.3.2 Canada
      • 5.2.3.2.1 Market size and forecast, by Product
      • 5.2.3.3 Mexico
      • 5.2.3.3.1 Market size and forecast, by Product
  • 5.3 Europe
    • 5.3.1 Key trends and opportunities
    • 5.3.2 Europe Market size and forecast, by Product
    • 5.3.3 Europe Market size and forecast, by country
      • 5.3.3.1 Germany
      • 5.3.3.1.1 Market size and forecast, by Product
      • 5.3.3.2 France
      • 5.3.3.2.1 Market size and forecast, by Product
      • 5.3.3.3 United Kingdom
      • 5.3.3.3.1 Market size and forecast, by Product
      • 5.3.3.4 Italy
      • 5.3.3.4.1 Market size and forecast, by Product
      • 5.3.3.5 Spain
      • 5.3.3.5.1 Market size and forecast, by Product
      • 5.3.3.6 Rest of Europe
      • 5.3.3.6.1 Market size and forecast, by Product
  • 5.4 Asia-Pacific
    • 5.4.1 Key trends and opportunities
    • 5.4.2 Asia-Pacific Market size and forecast, by Product
    • 5.4.3 Asia-Pacific Market size and forecast, by country
      • 5.4.3.1 China
      • 5.4.3.1.1 Market size and forecast, by Product
      • 5.4.3.2 Japan
      • 5.4.3.2.1 Market size and forecast, by Product
      • 5.4.3.3 India
      • 5.4.3.3.1 Market size and forecast, by Product
      • 5.4.3.4 Australia
      • 5.4.3.4.1 Market size and forecast, by Product
      • 5.4.3.5 Rest Of Asia Pacific
      • 5.4.3.5.1 Market size and forecast, by Product
  • 5.5 LAMEA
    • 5.5.1 Key trends and opportunities
    • 5.5.2 LAMEA Market size and forecast, by Product
    • 5.5.3 LAMEA Market size and forecast, by country
      • 5.5.3.1 Brazil
      • 5.5.3.1.1 Market size and forecast, by Product
      • 5.5.3.2 Saudi Arabia
      • 5.5.3.2.1 Market size and forecast, by Product
      • 5.5.3.3 South Africa
      • 5.5.3.3.1 Market size and forecast, by Product
      • 5.5.3.4 Rest of LAMEA
      • 5.5.3.4.1 Market size and forecast, by Product

CHAPTER 6: COMPANY LANDSCAPE

  • 6.1. Introduction
  • 6.2. Top winning strategies
  • 6.3. Product Mapping of Top 10 Player
  • 6.4. Competitive Dashboard
  • 6.5. Competitive Heatmap
  • 6.6. Key developments

CHAPTER 7: COMPANY PROFILES

  • 7.1 ASTRAZENECA PLC
    • 7.1.1 Company overview
    • 7.1.2 Company snapshot
    • 7.1.3 Operating business segments
    • 7.1.4 Product portfolio
    • 7.1.5 Business performance
    • 7.1.6 Key strategic moves and developments
  • 7.2 BOEHRINGER INGELHEIM GMBH
    • 7.2.1 Company overview
    • 7.2.2 Company snapshot
    • 7.2.3 Operating business segments
    • 7.2.4 Product portfolio
    • 7.2.5 Business performance
    • 7.2.6 Key strategic moves and developments
  • 7.3 ELI LILLY AND COMPANY
    • 7.3.1 Company overview
    • 7.3.2 Company snapshot
    • 7.3.3 Operating business segments
    • 7.3.4 Product portfolio
    • 7.3.5 Business performance
    • 7.3.6 Key strategic moves and developments
  • 7.4 GLAXOSMITHKLINE PLC
    • 7.4.1 Company overview
    • 7.4.2 Company snapshot
    • 7.4.3 Operating business segments
    • 7.4.4 Product portfolio
    • 7.4.5 Business performance
    • 7.4.6 Key strategic moves and developments
  • 7.5 NOVARTIS AG
    • 7.5.1 Company overview
    • 7.5.2 Company snapshot
    • 7.5.3 Operating business segments
    • 7.5.4 Product portfolio
    • 7.5.5 Business performance
    • 7.5.6 Key strategic moves and developments
  • 7.6 NOVO NORDISK
    • 7.6.1 Company overview
    • 7.6.2 Company snapshot
    • 7.6.3 Operating business segments
    • 7.6.4 Product portfolio
    • 7.6.5 Business performance
    • 7.6.6 Key strategic moves and developments
  • 7.7 SANOFI S.A.
    • 7.7.1 Company overview
    • 7.7.2 Company snapshot
    • 7.7.3 Operating business segments
    • 7.7.4 Product portfolio
    • 7.7.5 Business performance
    • 7.7.6 Key strategic moves and developments
  • 7.8 TAKEDA PHARMACEUTICAL COMPANY LIMITED
    • 7.8.1 Company overview
    • 7.8.2 Company snapshot
    • 7.8.3 Operating business segments
    • 7.8.4 Product portfolio
    • 7.8.5 Business performance
    • 7.8.6 Key strategic moves and developments
  • 7.9 johnson and johnson md&d
    • 7.9.1 Company overview
    • 7.9.2 Company snapshot
    • 7.9.3 Operating business segments
    • 7.9.4 Product portfolio
    • 7.9.5 Business performance
    • 7.9.6 Key strategic moves and developments
  • 7.10 MERCK and CO., INC.
    • 7.10.1 Company overview
    • 7.10.2 Company snapshot
    • 7.10.3 Operating business segments
    • 7.10.4 Product portfolio
    • 7.10.5 Business performance
    • 7.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 2. DIABETES THERAPEUTICS MARKET REVENUE, FOR INJECTABLES, BY REGION , 2020-2030,($MILLION)
  • TABLE 3. DIABETES THERAPEUTICS MARKET INJECTABLES BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 4. DIABETES THERAPEUTICS MARKET REVENUE, FOR ORAL ANTIDIABETIC DRUGS, BY REGION , 2020-2030,($MILLION)
  • TABLE 5. DIABETES THERAPEUTICS MARKET ORAL ANTIDIABETIC DRUGS BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 6. DIABETES THERAPEUTICS MARKET, BY REGION, 2020-2030,($MILLION)
  • TABLE 7. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 8. NORTH AMERICA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 9. U.S. DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 10. CANADA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 11. MEXICO DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 12. EUROPE DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 13. EUROPE DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 14. GERMANY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 15. FRANCE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 16. UNITED KINGDOM DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 17. ITALY DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 18. SPAIN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 19. REST OF EUROPE DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 20. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 21. ASIA-PACIFIC DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 22. CHINA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 23. JAPAN DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 24. INDIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 25. AUSTRALIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 26. REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 27. LAMEA DIABETES THERAPEUTICS MARKET, BY PRODUCT, 2020-2030,($MILLION)
  • TABLE 28. LAMEA DIABETES THERAPEUTICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
  • TABLE 29. BRAZIL DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 30. SAUDI ARABIA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 31. SOUTH AFRICA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 32. REST OF LAMEA DIABETES THERAPEUTICS MARKET BY PRODUCT 2020-2030,($MILLION)
  • TABLE 33.ASTRAZENECA PLC: COMPANY SNAPSHOT
  • TABLE 34.ASTRAZENECA PLC: OPERATING SEGMENTS
  • TABLE 35.ASTRAZENECA PLC: PRODUCT PORTFOLIO
  • TABLE 36.ASTRAZENECA PLC: NET SALES,
  • TABLE 37.ASTRAZENECA PLC: KEY STRATERGIES
  • TABLE 38.BOEHRINGER INGELHEIM GMBH: COMPANY SNAPSHOT
  • TABLE 39.BOEHRINGER INGELHEIM GMBH: OPERATING SEGMENTS
  • TABLE 40.BOEHRINGER INGELHEIM GMBH: PRODUCT PORTFOLIO
  • TABLE 41.BOEHRINGER INGELHEIM GMBH: NET SALES,
  • TABLE 42.BOEHRINGER INGELHEIM GMBH: KEY STRATERGIES
  • TABLE 43.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • TABLE 44.ELI LILLY AND COMPANY: OPERATING SEGMENTS
  • TABLE 45.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
  • TABLE 46.ELI LILLY AND COMPANY: NET SALES,
  • TABLE 47.ELI LILLY AND COMPANY: KEY STRATERGIES
  • TABLE 48.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 49.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 50.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 51.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 52.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 53.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 54.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 55.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 56.NOVARTIS AG: NET SALES,
  • TABLE 57.NOVARTIS AG: KEY STRATERGIES
  • TABLE 58.NOVO NORDISK: COMPANY SNAPSHOT
  • TABLE 59.NOVO NORDISK: OPERATING SEGMENTS
  • TABLE 60.NOVO NORDISK: PRODUCT PORTFOLIO
  • TABLE 61.NOVO NORDISK: NET SALES,
  • TABLE 62.NOVO NORDISK: KEY STRATERGIES
  • TABLE 63.SANOFI S.A.: COMPANY SNAPSHOT
  • TABLE 64.SANOFI S.A.: OPERATING SEGMENTS
  • TABLE 65.SANOFI S.A.: PRODUCT PORTFOLIO
  • TABLE 66.SANOFI S.A.: NET SALES,
  • TABLE 67.SANOFI S.A.: KEY STRATERGIES
  • TABLE 68.TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT
  • TABLE 69.TAKEDA PHARMACEUTICAL COMPANY LIMITED: OPERATING SEGMENTS
  • TABLE 70.TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT PORTFOLIO
  • TABLE 71.TAKEDA PHARMACEUTICAL COMPANY LIMITED: NET SALES,
  • TABLE 72.TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY STRATERGIES
  • TABLE 73.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT
  • TABLE 74.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS
  • TABLE 75.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO
  • TABLE 76.JOHNSON AND JOHNSON MD&D: NET SALES,
  • TABLE 77.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES
  • TABLE 78.MERCK AND CO., INC.: COMPANY SNAPSHOT
  • TABLE 79.MERCK AND CO., INC.: OPERATING SEGMENTS
  • TABLE 80.MERCK AND CO., INC.: PRODUCT PORTFOLIO
  • TABLE 81.MERCK AND CO., INC.: NET SALES,
  • TABLE 82.MERCK AND CO., INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.DIABETES THERAPEUTICS MARKET SEGMENTATION
  • FIGURE 2.DIABETES THERAPEUTICS MARKET,2020-2030
  • FIGURE 3.DIABETES THERAPEUTICS MARKET,2020-2030
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.DIABETES THERAPEUTICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.DIABETES THERAPEUTICS MARKET,BY PRODUCT,2020(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF INJECTABLES DIABETES THERAPEUTICS MARKET,2020-2030(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF ORAL ANTIDIABETIC DRUGS DIABETES THERAPEUTICS MARKET,2020-2030(%)
  • FIGURE 15.DIABETES THERAPEUTICS MARKET BY REGION,2020
  • FIGURE 16.U.S. DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 17.CANADA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 18.MEXICO DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 19.GERMANY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 20.FRANCE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 21.UNITED KINGDOM DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 22.ITALY DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 23.SPAIN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 24.REST OF EUROPE DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 25.CHINA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 26.JAPAN DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 27.INDIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 28.AUSTRALIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 29.REST OF ASIA PACIFIC DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 30.BRAZIL DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 31.SAUDI ARABIA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 32.SOUTH AFRICA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 33.REST OF LAMEA DIABETES THERAPEUTICS MARKET,2020-2030($MILLION)
  • FIGURE 34. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 35. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 36. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 37.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 38.COMPETITIVE DASHBOARD
  • FIGURE 39.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 40.ASTRAZENECA PLC.: NET SALES ,($MILLION)
  • FIGURE 41.BOEHRINGER INGELHEIM GMBH.: NET SALES ,($MILLION)
  • FIGURE 42.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
  • FIGURE 43.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 44.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 45.NOVO NORDISK.: NET SALES ,($MILLION)
  • FIGURE 46.SANOFI S.A..: NET SALES ,($MILLION)
  • FIGURE 47.TAKEDA PHARMACEUTICAL COMPANY LIMITED.: NET SALES ,($MILLION)
  • FIGURE 48.JOHNSON AND JOHNSON MD&D.: NET SALES ,($MILLION)
  • FIGURE 49.MERCK AND CO., INC..: NET SALES ,($MILLION)